Ovarian Cancer Clinical Trial

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)

Summary

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of Mirvetuximab Soravtansine in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

View Full Description

Full Description

Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to the tumor cells carrying a tumor-associated protein called folate receptor alpha (FRα). It is being developed as maintenance therapy for the treatment of subjects with recurrent platinum-sensitive, highgrade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression. Patients must have confirmation of FRα positivity by the Ventana FOLR1 Assay.

.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients must be ≥ 18 years of age
Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Patients must have a confirmed diagnosis of high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Patients must be willing to provide an archival tumor tissue block or slides, or must undergo a procedure to obtain a new biopsy using a low-risk, medically routine procedure for IHC confirmation of high FRα expression (reported as "positive") as defined by the Ventana FOLR1 Assay. Patients must be confirmed FRα-high as defined by FRα positivity of ≥ 75% of tumor membrane staining at ≥ 2+ intensity (PS2+) for entry into the study.

Prior BRCA testing on the tumor or prior germline testing is required for eligibility. If not done prior, tumor or germline testing will need to be done before study entry. Somatic and germline BRCA-positive patients must have received prior treatment with a PARPi in maintenance following first-line treatment.

Note: Local tumor or germline BRCA testing will be acceptable for stratification. If the patient has not been tested, recommend archival tumor samples to be assessed for tissue BRCA. All patients who have received prior first line PARPi maintenance and/or bevacizumab are eligible.

Patients' disease must have relapsed after 1 line (first line) of platinum-based chemotherapy and must be platinum-sensitive defined as progression greater than 6 months from last dose of primary platinum therapy.
Patients must be appropriate for, currently be on, or have completed platinum-based triplet therapy in the second line (recurrent PSOC).

After completion of triplet therapy and before randomization, patients must have received no less than 4 and no greater than 8 cycles of platinum-based triplet therapy in the second line, to include no less than 3 cycles of bevacizumab in combination with platinum-based chemotherapy. If the number of cycles received is less than 6 due to toxicity, this must be documented and toxicity assessed as unlikely related to bevacizumab.

Note: A minimum of 4 cycles of combination chemotherapy is required. If carboplatin, paclitaxel, gemcitabine, or pegylated liposomal doxorubicin (PLD) is stopped due to toxicity, up to 4 additional cycles of single agent in combination with bevacizumab is acceptable if appropriately documented.

After completion of triplet therapy and before randomization: In the case of interval secondary cytoreductive surgery, patients are permitted to have received only 2 cycles of bevacizumab if given in combination with the last 3 cycles of platinum-based triplet therapy in the second line. In the case of primary cytoreductive surgery before secondline platinum-based triplet therapy, patients must have received no fewer than 3 cycles of bevacizumab in combination with platinum-based chemotherapy after their surgery and before randomization.
Patients either will receive (per investigator's choice), must be receiving, or have received paclitaxel, gemcitabine, or pegylated liposomal doxorubicin as the partner drug to platinum-based triplet therapy in the second line.
After completion of triplet therapy and before randomization, patients must have achieved a CR, PR, or SD, per the investigator, in the second line to be eligible for randomization into the study population. All patients will have CT or MRI scans and CA-125 measurements at least 3 weeks but no more than 8 weeks after their last planned dose of triplet therapy and before randomization.
Patients must be randomized no later than 8 weeks from the last dose of platinum-based triplet therapy in the second line.

After completion of triplet therapy and before randomization, patients must meet one of the following criteria:

Have at least 1 lesion that meets the definition of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (radiologically measured by the investigator), and determined by the investigator to either have SD or a PR to their treatment; or
Have persistently elevated CA-125 without measurable disease and determined by the investigator to have either SD or a PR to their treatment; or
Have clinically no evidence of disease by both radiographic interpretation by the investigator and normalization of their CA-125, determined to be a CR.
Patients must have stabilized or recovered (to Grade 1 or baseline) from all prior therapy-related toxicities (except alopecia).
Patients must have completed any major surgery at least 4 weeks before the first dose of study treatment (either Run-In or maintenance therapy) and have recovered or stabilized from the side effects of prior surgery before the first dose of treatment on study.

Patients must have adequate hematologic, liver, and kidney functions defined as follows:

Absolute neutrophil count (ANC) ≥ 1.5 × 109/L (1500/μL) without granulocyte colony-stimulating factor in the prior 10 days or long-acting white blood cell (WBC) growth factors in the prior 10 days of C1D1 of maintenance treatment.
Platelet count ≥ 100 × 109/L (100,000/μL) without platelet transfusion in the prior 10 days of C1D1 of maintenance treatment
Hemoglobin ≥ 9.0 g/dL without packed red blood cell (PRBC) transfusion in the prior 10 days of C1D1 of maintenance treatment
Serum creatinine ≤ 1.5 × upper limit of normal (ULN)
Aspartate aminotransferase and alanine aminotransferase ≤ 3.0 × ULN
Serum bilirubin ≤ 1.5 × ULN (patients with documented diagnosis of Gilbert syndrome are eligible if total bilirubin < 3.0 × ULN)
Serum albumin ≥ 2 g/dL
Patients must be willing and able to sign the informed consent form (ICF) and to adhere to the protocol requirements.
Females of childbearing potential (FCBP) must agree to use highly effective contraceptive method(s) (as defined in Section 5.10.7) while on study medication and for at least 3 months after the last dose.
FCBP must have a negative pregnancy test within 4 days before the first dose of therapy.

Exclusion Criteria:

Patients with endometrioid, clear cell, mucinous, or sarcomatous histology; mixed tumors containing any of the above histologies; or low-grade/borderline ovarian tumor

More than one line of prior chemotherapy before current/planned triplet therapy. Lines of prior anticancer therapy are counted with the following considerations:

Neoadjuvant ± adjuvant therapies are considered 1 line of therapy if the neoadjuvant and adjuvant correspond to 1 fully predefined regimen; otherwise, they are counted as 2 prior regimens.
Maintenance therapy (eg, bevacizumab, PARPi) will be considered part of the preceding line of therapy (ie, not counted independently).
Change due to toxicity will be considered part of the proceeding line of therapy.
Patients with PD while on or following platinum-based triplet therapy
After completion of triplet therapy and prior to randomization: Patients who receive an intervening dose of bevacizumab after the last dose of triplet therapy before randomization
Patients with prior wide-field radiotherapy affecting at least 20% of the bone marrow
Patients with > Grade 1 peripheral neuropathy per Common Terminology Criteria for Adverse Events (CTCAE)
7. Patients with active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing treatment/monitoring, such as uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and/or monocular vision

Patients with serious concurrent illness or clinically relevant active infection, including but not limited to the following:

Active hepatitis B or C infection (whether or not on active antiviral therapy)
HIV infection
Active cytomegalovirus infection
Any other concurrent infectious disease requiring intravenous (IV) antibiotics within 2 weeks before the first dose of maintenance therapy Note: Testing at screening is not required for the above infections unless clinically indicated.
Patients with a history of multiple sclerosis or other demyelinating diseases and/or Lambert-Eaton syndrome (paraneoplastic syndrome)

Patients with clinically significant cardiac disease including, but not limited to, any of the following:

Myocardial infarction ≤ 6 months prior to C1D1 of maintenance treatment
Unstable angina pectoris
Uncontrolled congestive heart failure (New York Heart Association > class II)
Uncontrolled ≥ Grade 3 hypertension (per CTCAE)
Uncontrolled cardiac arrhythmias
Patients with a history of hemorrhagic or ischemic stroke within 6 months before enrollment
Patients with a history of cirrhotic liver disease (Child-Pugh Class B or C)
Patients with a previous clinical diagnosis of noninfectious interstitial lung disease, including noninfectious pneumonitis (exception: Grade 1 noninfectious pneumonitis diagnosed on or within 6 weeks after treatment with an immunotherapeutic agent used in the treatment of their malignancy that has resolved per investigator or resolution of the radiologic findings)
History of bowel obstruction (including sub-occlusive disease) related to underlying disease within 6 months before the start of maintenance study treatment (triplet therapy for Run-In patients).
History of abdominal fistula or gastrointestinal perforation
Intra-abdominal abscess, evidence of rectosigmoid involvement by pelvic examination, bowel involvement on CT scan, or clinical symptoms of bowel obstruction within 4 weeks prior to randomization (or within 4 weeks prior to starting triplet therapy for Run- In patients)
Clinically significant proteinuria: urine-protein to creatinine (UPC) ratio ≥ 1.0 or urine dipstick result ≥ 2+; patients with UPC ratio ≥ 1.0 or ≥ 2+ proteinuria should undergo 24-hour urine collection and must show result ≤ 1 g of protein in a 24-hour period.
History of Grade 4 thromboembolic events
Patients not appropriate for bevacizumab 15 mg/kg dosing at the start of maintenance therapy as per the treating physician
Patients requiring use of folate-containing supplements (eg, folate deficiency)
Patients with prior hypersensitivity to monoclonal antibodies (mAbs)
Women who are pregnant or breastfeeding
Patients who received prior treatment with MIRV or other FRα-targeting agents
Patients with untreated or symptomatic central nervous system metastases

Patients with a history of other malignancy within 3 years prior to signing study consent

Note: Patients with tumors with a negligible risk for metastasis or death (eg, controlled basal cell carcinoma or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast) are eligible.

Prior known hypersensitivity reactions to study drugs or any of their excipients

Study is for people with:

Ovarian Cancer

Phase:

Phase 3

Estimated Enrollment:

418

Study ID:

NCT05445778

Recruitment Status:

Recruiting

Sponsor:

ImmunoGen, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 147 Locations for this study

See Locations Near You

USA Mitchell Cancer Institute
Mobile Alabama, 36604, United States More Info
Stefanie White
Contact
251-445-9834
[email protected]
Jennifer Scalici, MD
Principal Investigator
Honor Health Cancer Care, Biltmore, 2222 E. Highland Ave, #400
Phoenix Arizona, 85016, United States More Info
Kelly Fillbrandt
Contact
480-583-7485
[email protected]
Lyndsay Willmott
Principal Investigator
John Muir Health
Concord California, 94520, United States More Info
Peggy Newsom
Contact
925-674-2580
[email protected]
Babak Edraki, MD
Principal Investigator
City of Hope
Irvine California, 92618, United States More Info
Joshua Cohen, MD
Contact
626-218-1133
[email protected]
Contact
877-467-3411
Joshua Cohen, MD
Principal Investigator
Kaiser Permanente Irvine Medical Center, 6650 Alton Pkwy
Irvine California, 92618, United States More Info
Devansu Tewari
Principal Investigator
UC San Diego Health - Moores Cancer Center
La Jolla California, 92093, United States More Info
Alexandrea Cronin, MPH, CCRC
Contact
858-822-3975
[email protected]
Ramez Eskander
Principal Investigator
Kaiser Permanente Los Angeles Medical Center, 4950 Sunset Blvd., 6th Floor
Los Angeles California, 90027, United States More Info
Devansu Tewari
Principal Investigator
UCI Health- Chao Family Comprehensive Cancer Center
Orange California, 92868, United States More Info
Krishnansu Tewari, MD
Contact
[email protected]
Krishnansu Tewari, MD
Principal Investigator
Stanford University
Palo Alto California, 94304, United States More Info
Mary Herrera
Contact
[email protected]
Jonathan Berek, MD
Principal Investigator
Kaiser Permanente Riverside Medical Center, 10800 Magnolia Ave
Riverside California, 92505, United States More Info
Devansu Tewari
Principal Investigator
Kaiser Permanente Zion Medical Center, 4647 Zion Ave
San Diego California, 92120, United States More Info
Devansu Tewari
Principal Investigator
Kaiser Permanente San Marcos Medical Offices, 400 Craven Road
San Marcos California, 92069, United States More Info
Devansu Tewari
Principal Investigator
Olive View UCLA Medical Center Inpatient Pharmacy, 14445 Olive View Dr, Rm 1C101
Sylmar California, 91342, United States More Info
Bianca Alcantar
Contact
[email protected]
Carolyn Haunschild
Principal Investigator
Broward Health Medical Center
Fort Lauderdale Florida, 33316, United States More Info
Linda Borus
Contact
954-712-7969
[email protected]
Scott Jordan, MD
Principal Investigator
Regional Cancer Center/ Florida Gynecologic Oncology
Fort Myers Florida, 33905, United States More Info
Julia Malfeld
Contact
239-343-9660
[email protected]
Edward Grendys, MD
Principal Investigator
Baptist MD Anderson Cancer Center
Jacksonville Florida, 32207, United States More Info
Rebecca Deya
Contact
904-202-7468
[email protected]
Lauren Hand, MD
Principal Investigator
Mount Sinai Comprehensive Cancer Center
Miami Florida, 33140, United States More Info
Yvonne Enriquez Nunez
Contact
305-674-2625
[email protected]
Brian Slomovitz, MD
Principal Investigator
Sarasota Memorial Health Care System
Sarasota Florida, 34239, United States More Info
Angele Price
Contact
941-917-3614
[email protected]
Beverly Long, MD
Principal Investigator
Northside Hospital
Atlanta Georgia, 30342, United States More Info
Meaghan Tenney, MD
Principal Investigator
Rush University Medical Center, 1725 West Harrison Street
Chicago Illinois, 60612, United States More Info
Lois Winkelman, RN
Contact
312-942-2417
Summer Dewdney
Principal Investigator
University of Chicago Medicine, 5841 S Maryland Ave, MC 2115
Chicago Illinois, 60637, United States More Info
Katrina Cabrera
Contact
773-834-6413
[email protected]
John Moroney, MD
Principal Investigator
Indiana University
Indianapolis Indiana, 46202, United States More Info
Liz Crist
Contact
[email protected]
Lisa Landrum, MD
Principal Investigator
St Vincent Gynecologic Oncology
Indianapolis Indiana, 46260, United States More Info
Cynthia Cruz, CCRP
Contact
317-415-6747
[email protected]
Michael Callahan, MD
Principal Investigator
University of Iowa Health Care
Iowa City Iowa, 52242, United States More Info
Jessica Landgrebe
Contact
[email protected]
David Bender, MD
Principal Investigator
University of Kansas Cancer Center
Westwood Kansas, 66205, United States More Info
Andrea D Jewell, MD
Principal Investigator
Baptist Health Lexington
Lexington Kentucky, 40503, United States More Info
Karli Herald
Contact
866-213-3025
[email protected]
Hope Cottrill, MD
Principal Investigator
University of Kentucky
Lexington Kentucky, 40536, United States More Info
Ashley Walton-Robbins
Contact
859-218-1758
[email protected]
Rachel Miller, MD
Principal Investigator
LSUHSC
New Orleans Louisiana, 70112, United States More Info
Maria Stambaugh
Contact
504-210-1846
Amelia Jernigan, MD
Principal Investigator
Ochsner Clinic Foundation
New Orleans Louisiana, 70121, United States More Info
Rachael Chrzan
Contact
504-842-3910
[email protected]
Katrina Wade, MD
Principal Investigator
Maine Medical Center
Scarborough Maine, 04074, United States More Info
Leslie Bradford, MD
Principal Investigator
Greater Baltimore Medical Center
Baltimore Maryland, 21204, United States More Info
Laura M Cucci
Contact
443-849-3122
[email protected]
Fong Liu, MD
Principal Investigator
Sinai Hospital of Baltimore, Inc.
Baltimore Maryland, 21215, United States More Info
Judy Bosley, RN
Contact
410-601-6120
Pallavi Kumar, MD
Principal Investigator
Johns Hopkins Medical Institute
Baltimore Maryland, 21287, United States More Info
Johns Hopkins
Contact
410-614-1361
[email protected]
Stephanie Gaillard, MD
Principal Investigator
Baystate Gynecologic Oncology - Tolosky Center
Springfield Massachusetts, 01107, United States More Info
Tashanna Myers, MD
Principal Investigator
Corewell Health
Grand Rapids Michigan, 49503, United States More Info
Esther Peariso
Contact
616-486-0358
Gregory Gressel, MD
Principal Investigator
Minnesota Oncology Hematology, P.A. (USOR)
Maplewood Minnesota, 55109, United States More Info
Jinan Ali
Contact
[email protected]
Jessica Thomes-Pepin, MD
Principal Investigator
Nebraska Methodist Hospital
Omaha Nebraska, 68114, United States More Info
Kathryn Bartz
Contact
[email protected]
Brent Tierney, MD
Principal Investigator
Center of Hope at Renown Medical Center
Reno Nevada, 89511, United States More Info
Shannon Pierpoint
Contact
775-327-4673
Peter Lim, MD
Principal Investigator
Dartmouth Hitchcock Medical, One Medical Center Drive
Lebanon New Hampshire, 03756, United States More Info
Christina Seymour
Contact
603-653-9922
[email protected]
Ilana Cass
Principal Investigator
John Theurer Cancer Center, University Medical Center, 92 Second Street
Hackensack New Jersey, 07601, United States More Info
Donna McNamara
Contact
[email protected]
Contact
616-486-6000
Donna McNamara
Principal Investigator
The Valley Hospital -Luckow Pavilion
Paramus New Jersey, 07652, United States More Info
Simran Kaur
Contact
201-634-5792
Eleonora Teplinsky, MD
Principal Investigator
Holy Name Medical Center
Teaneck New Jersey, 07666, United States More Info
Patty Kiledjian
Contact
201-541-6312
Sharyn Lewin, MD
Principal Investigator
New York Oncology Hematology, P.C. (USOR)
Albany New York, 12206, United States More Info
Josephine Faruol
Contact
[email protected]
Heidi E Godoy, MD
Principal Investigator
Perlmutter Cancer Center at NYU Langone Health-Long Island
Mineola New York, 11501, United States More Info
Bhavana Pothuri, MD
Principal Investigator
Perlmutter Cancer Center at NYU Langone Health
New York New York, 10016, United States More Info
Bhavana Pothuri, MD
Principal Investigator
Mount Sinai Hospital
New York New York, 10029, United States More Info
Neha Kumarley
Contact
212-824-7859
[email protected]
Monica Prasad-Hayes, MD
Principal Investigator
Northwell Health Cancer Institute
New York New York, 11042, United States More Info
Mary Agnes Templeton
Contact
516-734-8979
[email protected]
Charline Watts
Contact
516- 734- 8496
[email protected]
Veena John, MD
Principal Investigator
Womens Cancer Care Associates
New York New York, 12208, United States More Info
NICOLINA SURIANO
Contact
518-458-1390
[email protected]
Joyce Barlin, MD
Principal Investigator
UNC-Chapel Hill
Chapel Hill North Carolina, 27514, United States More Info
Jada Jones
Contact
919-918-1815
[email protected]
Linda Van Le, MD
Principal Investigator
Duke Cancer Center
Durham North Carolina, 27710, United States More Info
Jennifer Mewshaw
Contact
919-684-3780
[email protected]
Angeles Alvarez Secord, MD
Principal Investigator
University of Cincinnati
Cincinnati Ohio, 45219, United States More Info
Amanda Jackson, MD
Principal Investigator
Ohio State University
Columbus Ohio, 43210, United States More Info
Sam Allinger
Contact
614-293-8371
[email protected]
Floor Backes, MD
Principal Investigator
Kettering Health
Kettering Ohio, 45429, United States More Info
Daniel Geyer
Contact
937-395-6017
[email protected]
Thomas Reid, MD
Principal Investigator
OU Health Stephenson Cancer Center
Oklahoma City Oklahoma, 73104, United States More Info
Christine Pappaterra
Contact
405-271-8707
[email protected]
Christina Washington, MD
Principal Investigator
Oklahoma Cancer Specialists and Research Institute
Tulsa Oklahoma, 74146, United States More Info
Melissa Powell
Contact
[email protected]
Michael Gold, MD
Principal Investigator
Willamette Valley Cancer Institute and Research Center (USOR)
Eugene Oregon, 97401, United States More Info
Jeanne Schaffer
Contact
[email protected]
Charles K Anderson, MD
Principal Investigator
Northwest Cancer Specialists, P.C. (USOR)
Portland Oregon, 97227, United States More Info
Jennifer Thompson, CRC,RN
Contact
[email protected]
Erin A Salinas, MD
Principal Investigator
OHSU Center for Health & Healing, Building 2 (CHH2), 3485 S Bond Ave
Portland Oregon, 97239, United States More Info
Yukie Bean, CCRP
Contact
503-494-5044
[email protected]
Elizabeth Munro
Principal Investigator
Allegheny Health Network
Pittsburgh Pennsylvania, 15224, United States More Info
Madeline Rigatti
Contact
[email protected]
Sarah Crafton, MD
Principal Investigator
Sidney Kimmel Cancer Center Asplundh Cancer Pavilion
Willow Grove Pennsylvania, 19090, United States More Info
Ashley Douglas
Contact
215-481-4429
[email protected]
Tommy Buchanan
Principal Investigator
Sanford Gynecologic Oncology, 1309 W. 17th street
Sioux Falls South Dakota, 57104, United States More Info
Maria Bell
Contact
605-312-3250
[email protected]
Maria Bell
Principal Investigator
The West Clinic, PLLC dba West Cancer Center
Germantown Tennessee, 38138, United States More Info
Robin Patterson
Contact
901-683-0055
[email protected]
Michael Ulm, MD
Sub-Investigator
Texas Oncology, P.A. (USOR)
Austin Texas, 78731, United States More Info
Marian Heaven
Contact
[email protected]
Lynne Knowles, MD
Principal Investigator
Texas Oncology - DFWW (USOR)
Bedford Texas, 76022, United States More Info
Deborah Arant-Daigle
Contact
[email protected]
Mark J Messing, MD
Principal Investigator
Texas Oncology-Dallas Presbyterian Hospital (USOR)
Dallas Texas, 75231, United States More Info
Nancy Jones
Contact
[email protected]
Mark Messing
Principal Investigator
Texas Oncology (USOR)
Fort Worth Texas, 76104, United States More Info
Lynora (Nori) Sullivan
Contact
[email protected]
Noelle G Cloven, MD
Principal Investigator
Texas Oncology - San Antonio (USOR)
San Antonio Texas, 78240, United States More Info
Debora E Lind
Contact
[email protected]
Antonio Santillan-Gomez, MD
Principal Investigator
University of Virginia
Charlottesville Virginia, 22908, United States More Info
Hannah Snow
Contact
[email protected]
Linda Duska, MD
Principal Investigator
Virginia Oncology Associates (USOR)
Norfolk Virginia, 23502, United States More Info
Jenny Marks
Contact
[email protected]
Michael McCollum, MD
Principal Investigator
Virginia Commonwealth University (VCU)- Massey Comprehensive Cancer Center
Richmond Virginia, 23298, United States More Info
CTO operations
Contact
804-628-6430
[email protected]
Leslie Randall, MD
Principal Investigator
Westmead Hospital
Westmead New South Wales, 2145, Australia More Info
Gold Coast University Hospital
Southport Queensland, 4215, Australia More Info
Grampians Health Service
Ballarat Victoria, 3149, Australia More Info
Cabrini Health
Brighton Victoria, 3144, Australia More Info
Monash Health
Clayton Victoria, 3168, Australia More Info
Peter Maccallum Cancer Centre
Melbourne Victoria, 3000, Australia More Info
Epworth Health
Richmond Victoria, 3121, Australia More Info
Bendat Family Comprehensive Cancer Centre St John of God - Subiaco Hospital
Subiaco , 6008, Australia More Info
Imeldaziekenhuis, Apotheek Klinische Studies, Imeldalaan 9 Centraal Magazjin
Bonheiden , 2820, Belgium More Info
Cliniques Universitaires St-Luc Woluwe-Saint-Lambert
Brussel , 1200, Belgium More Info
GHDC Grand Hôpital de Charleroi, Site Notre-Dame, Grand Rue 3
Charleroi , 6000, Belgium More Info
AZ Sint Lucas Gent, Groenebriel 1
Gent , 9000, Belgium More Info
UZ Leuven, Apotheek Klinische studies, Herestraat, 49
Leuven , 3000, Belgium More Info
CHU UCL Namur - Site Sainte-Elisabeth, Route (Road) 471 Place Louise Godin 15, Oncology Day Hospital, 3rd Floor
Namur , 5000, Belgium More Info
AZ Delta apotheek, Tav Klinische studies, Kwadestraat 78
Roeselare , 8800, Belgium More Info
Tom Baker Cancer Centre, Alberta Health Services
Calgary Alberta, T2N 4, Canada More Info
Edith-Romy Nsangou
Contact
403-521-3784
[email protected]
Prafull Ghatage, MD
Principal Investigator
University of Alberta - Cross Cancer Institute (CCI)
Edmonton Alberta, T6G1Z, Canada More Info
Shalyn Dafoe
Contact
780-391-7686
Jennifer Rauw, MD
Principal Investigator
BC Cancer - Vancouver
Vancouver British Columbia, V5Z4E, Canada More Info
Jeff Gardner
Contact
1-604-877-6000
Alannah Smrke, MD
Principal Investigator
Juravinski Cancer Centre
Hamilton Ontario, L8V 5, Canada More Info
Nidhi Kumar-Tyagi, MD
Contact
905-387-9495
Nidhi Kumar-Tyagi, MD
Principal Investigator
Kinston Health Sciences Center - KGH Site
Kingston Ontario, K7L 2, Canada More Info
Julie Holiday
Contact
613-549-6666
Andrew Robinson, MD
Principal Investigator
The Ottawa Hospital Cancer Centre
Ottawa Ontario, K1H 8, Canada More Info
Johanne Weberpals, MD
Contact
613-737-7700
[email protected]
Johanne Weberpals, MD
Principal Investigator
Princess Margaret Cancer Centre
Toronto Ontario, M5G 2, Canada More Info
Amit Oza, MD
Principal Investigator
Universite de Montreal - Hopital Maisonneuve-Rosemont (HMR)
Montreal Quebec, H1T 2, Canada More Info
Lara deGuerke, MD
Contact
514-252-3400
[email protected]
Lara deGuerke, MD
Principal Investigator
Centre Hospitalier de L'Universite de Montreal - Centre de Recherche
Montreal Quebec, H2XOA, Canada More Info
Diane Provencher, MD
Contact
514-890-8444
[email protected]
Diane Provencher, MD
Principal Investigator
McGill University Health Centre
Montreal Quebec, H4A3J, Canada More Info
Mohamed Bakir
Contact
5149341934
[email protected]
Lucy Gilbert, MD
Principal Investigator
CHUS - Hôpital Fleurimont
Sherbrooke Quebec, J1H5N, Canada More Info
Paul Bessette, MD
Contact
819-821-8000
[email protected]
Paul Bessette, MD
Principal Investigator
University Hospital Brno
Brno , 625 0, Czechia More Info
Nemocnice AGEL Nový Jicín a.s.
Nový Jicín , 741 0, Czechia More Info
University Hospital Ostrava
Ostrava Poruba , 708 5, Czechia More Info
General University Hospital in Prague
Prague , 12851, Czechia More Info
Carmel Medical Centre
Haifa , 34362, Israel More Info
Wolfson Medical Centre
Holon , 58220, Israel More Info
Hadassah Medical Ctr. Ein Kerem. Sharett Institute of oncology
Jerusalem , 91120, Israel More Info
Shaare Zedek Medical Centre
Jerusalem , 94360, Israel More Info
Meir Medical Centre
Kefar Sava , 44281, Israel More Info
Rabin Medical Centre
Petah Tikva , 49414, Israel More Info
Tel Aviv Sourasky Medical Center
Tel Aviv Yaffo , 64239, Israel More Info
Policlinico S. Orsola-Malpighi
Bologna , 40138, Italy More Info
AOU Careggi
Firenze , 50134, Italy More Info
ASST Ospedale Alessandro Manzoni
Lecco , 23900, Italy More Info
Azienda USL Toscana Nord Ovest Ospedale San Luca
Lucca , 55100, Italy More Info
IRST - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Meldola , 47121, Italy More Info
IRCCS San Raffaele
Milano , 20132, Italy More Info
Fondazione IRCCS Istituto Nazionale dei Tumori
Milano , 20133, Italy More Info
Ospedale di Mirano
Mirano , 30035, Italy More Info
AOU di Parma
Parma , 43126, Italy More Info
AUSL Piacenza Ospedale Guglielmo da Saliceto
Piacenza , 29121, Italy More Info
Nuovo Ospedale di Prato - Santo Stefano
Prato , 59100, Italy More Info
Fondazione Policlinico Universitario A. Gemelli IRCCS
Rome , 168, Italy More Info
National Cancer Center
Goyang Gyeonggi-do, 10408, Korea, Republic of More Info
CHA University - Bundang CHA General Hospital
Seongnam Gyeonggi-do, 13496, Korea, Republic of More Info
Seoul National University Bundang Hospital
Seongnam Gyeonggi-do, 13620, Korea, Republic of More Info
Keimyung Dongsan University Hospital
Daegu , 42601, Korea, Republic of More Info
Korea University Anam Hospital
Seoul , 02841, Korea, Republic of More Info
Seoul National University Hospital
Seoul , 03080, Korea, Republic of More Info
Asan Medical Center
Seoul , 05505, Korea, Republic of More Info
Gangnam Severance Hospital, Yonsei University Health System
Seoul , 06273, Korea, Republic of More Info
Samsung Medical Center
Seoul , 06351, Korea, Republic of More Info
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul , 06591, Korea, Republic of More Info
Korea University Guro Hospital
Seoul , 08308, Korea, Republic of More Info
Severance Hospital, Yonsei University Health System
Seoul , 3722, Korea, Republic of More Info
The Medical City -Ortigas
Pasig Metro Manila, 1600, Philippines More Info
Cardinal Santos Medical Center
San Juan Metro Manila, 1502, Philippines More Info
East Avenue Medical Centre
Quezon City , 1100, Philippines
Hospital Universitario Vall d'Hebron, CT Pharm General Building-Floor B, Passeig Vall d'Hebron
Barcelona , 08035, Spain More Info
Instituto Catalán de Oncologia, 199-203 Av Gra Via CT Pharmacy, Hospital Duran i Reynals
Barcelona , 08035, Spain More Info
Hospital Clinic de Barcelona (Hospital Clinic i Provincial)
Barcelona , 8008, Spain More Info
Hospital Universitario de A Coruña (CHUAC)
Coruña , 15009, Spain More Info
ICO-Hospital Universitario de Girona
Girona , 17007, Spain More Info
Clínica Universidad de Navarra
Madrid , 28027, Spain More Info
Hospital La Paz CT Pharmacy, 261 Paseo Castellana, North Building Ground Floor
Madrid , 28046, Spain More Info
Clinica Universitaria Navarra Pamplona
Pamplona , 31008, Spain More Info
Hospital Clinico Universitario de Valencia
Valencia , 46010, Spain More Info
The Royal Marsden NHS Foundation Trust
Fulham London, SW3 6, United Kingdom More Info
The Royal Marsden NHS Foundation Trust
Sutton Surrey, SM2 5, United Kingdom More Info
Cheltenham General Hospital
Cheltenham , GL53 , United Kingdom More Info
Guy's and St Thomas' NHS Foundation Trust
London , SE1 9, United Kingdom More Info
Mount Vernon Cancer Centre East and North Hertfordshire NHS Trust
Northwood , HA6 2, United Kingdom More Info
Southampton University NHS Trust
Southampton , SO16 , United Kingdom More Info
Singleton Hospital
Swansea , SA2 8, United Kingdom More Info

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Phase:

Phase 3

Estimated Enrollment:

418

Study ID:

NCT05445778

Recruitment Status:

Recruiting

Sponsor:


ImmunoGen, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.